Clinical trials: in Bulgaria
Haemophilia A and B With and Without Inhibitors
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
- Trial name
- Explorer10 (NCT05135559)
- Testing
- Concizumab
- Where
- 91 sites in United States, Algeria and 22 more
- Volunteers
- 153 people
- Sponsor
- Novo Nordisk A/S
Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
- Trial name
- AERIFY-4 (NCT06208306)
- Testing
- Itepekimab (SAR440340)
- Where
- 223 sites in United States, Argentina and 30 more
- Volunteers
- 669 people
- Sponsor
- Sanofi
Acute Bacterial Skin and Skin Structure Infections
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in…
- Trial name
- NCT03137173
- Testing
- ceftobiprole medocaril, vancomycin+aztreonam
- Where
- 34 sites in United States, Bulgaria and 2 more
- Volunteers
- 679 people
- Sponsor
- Basilea Pharmaceutica
Ulcerative Colitis
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative…
- Trial name
- SELECTIONLTE (NCT02914535)
- Testing
- Filgotinib
- Where
- 323 sites in United States, Argentina and 37 more
- Volunteers
- 1,173 people
- Sponsor
- Alfasigma S.p.A.
Healthy Volunteers
Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects
A clinical trial to investigate the safety and tolerability of single and multiple intranasal (through the nose) dosing with the study drug CHF6467 in 68 healthy adult subjects.
- Trial name
- NCT07163182
- Testing
- CHF6467 Part 1 (SAD), CHF6467 Part 2 (MAD)
- Where
- Bulgaria
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Relapsing Multiple Sclerosis
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS.
- Trial name
- FENhance 2 (NCT04586023)
- Testing
- Fenebrutinib, Teriflunomide
- Where
- 106 sites in United States, Austria and 15 more
- Volunteers
- 751 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS).
- Trial name
- FENtrepid (NCT04544449)
- Testing
- Fenebrutinib, Ocrelizumab
- Where
- 190 sites in United States, Argentina and 26 more
- Volunteers
- 985 people
- Sponsor
- Hoffmann-La Roche
ALK Positive Malignancies
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with…
- Trial name
- NCT02584933
- Testing
- ceritinib
- Where
- 71 sites in United States, Australia and 19 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use.
- Trial name
- explorer8 (NCT04082429)
- Testing
- Concizumab
- Where
- 113 sites in United States, Algeria and 31 more
- Volunteers
- 156 people
- Sponsor
- Novo Nordisk A/S
Seasonal Influenza
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase…
- Trial name
- NCT06602024
- Testing
- mRNA-1010, Fluarix®, Influsplit® Tetra
- Where
- 301 sites in United States, Belgium and 9 more
- Volunteers
- 40,805 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Carcinoma, Non-Small-Cell Lung
THIO Sequenced With Cemiplimab in Advanced NSCLC
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®).
- Trial name
- NCT05208944
- Testing
- 6-Thio-2'-Deoxyguanosine, Cemiplimab
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 227 people
- Sponsor
- Maia Biotechnology
Colorectal Cancer
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection.
- Trial name
- NCT06515821
- Testing
- ONCOSCREEN
- Where
- 8 sites in Bulgaria, France and 4 more
- Volunteers
- 4,100 people
- Sponsor
- Firalis SA
Type B Aortic Dissection
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
This clinical trial is a prospective, multicenter, open label study designed to evaluate the effectiveness and the safety of the Allay® Aortic Stent as adjunctive endovascular treatment of Type B aortic dissection in patients…
- Trial name
- EXTENSO (NCT06675617)
- Testing
- Allay Aortic Stent
- Where
- 21 sites in Austria, Belgium and 6 more
- Volunteers
- 72 people
- Sponsor
- Intressa Vascular SA
Myositis
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM).
- Trial name
- NCT05895786
- Testing
- PF-06823859
- Where
- 138 sites in United States, Argentina and 18 more
- Volunteers
- 318 people
- Sponsor
- Pfizer
Dermatomyositis
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM).
- Trial name
- VALOR (NCT05437263)
- Testing
- Brepocitinib
- Where
- 109 sites in United States, Argentina and 20 more
- Volunteers
- 241 people
- Sponsor
- Priovant Therapeutics, Inc.
Breast Cancer
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
A longitudinal, non-interventional study with trastuzumab deruxtecan for patients with HER2-low expressing unresectable or metastatic breast cancer in Bulgaria and Slovenia
- Trial name
- EXPLORE (NCT06727227)
- Testing
- trastuzumab deruxtecan
- Where
- 14 sites in Bulgaria, Slovenia
- Volunteers
- 138 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
- Trial name
- NCT02273375
- Testing
- MEDI4736
- Where
- 271 sites in United States, Australia and 17 more
- Volunteers
- 1,415 people
- Sponsor
- Canadian Cancer Trials Group
Major Depressive Disorder
Study to Assess the Safety and Effectiveness of NMRA-335140-501
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD).
- Trial name
- NCT06029439
- Testing
- NMRA-335140
- Where
- 178 sites in United States, Brazil and 9 more
- Volunteers
- 904 people
- Sponsor
- Neumora Therapeutics, Inc.
Breast Cancer, Solid Tumors
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2).
- Trial name
- NCT05262400
- Testing
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 235 people
- Sponsor
- Pfizer
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active…
- Trial name
- Ametrine-1 (NCT06589986)
- Testing
- Afimkibart
- Where
- 184 sites in United States, Argentina and 28 more
- Volunteers
- 400 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.